Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11.
Cancer Lett
; 245(1-2): 331-6, 2007 Jan 08.
Article
em En
| MEDLINE
| ID: mdl-16504379
ABSTRACT
The development of T cell-based immunotherapies of cancer depends on the identification of tumor-associated antigens capable of eliciting tumor-directed cytotoxic T cell responses. In malignant glioma the number of well-defined target antigens for cytotoxic T lymphocytes (CTLs) is still very limited. Recently, we demonstrated the abundant and specific overexpression of the transcription factor SOX11 in malignant glioma. Here, we describe the SOX11-derived peptide LLRRYNVAKV which is capable of inducing human leukocyte antigen-A*0201-restricted and tumor-reactive CTLs. This novel CTL epitope may serve as an attractive candidate for a T cell-based immunotherapy of glioma.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Proteínas de Grupo de Alta Mobilidade
/
Epitopos de Linfócito T
/
Glioma
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article